Oculis Holding AG
CHFinancials
Valuation Metrics
Oculis Holding AG's Market Cap is $499M. At end of 2025 it was $1.07B. Ranked #2749 of 3,116 in US market (top 88%), #1202 of 1,472 on NASDAQ (top 82%), #217 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $499M | US#2,749/3,116 Sec#217/265 |
| Revenue | $607889.00 | US#2,848/3,116 Sec#189/265 |
| Net Income | $-115M | US—/3,116 Sec—/265 |
| Total Assets | $307M | US#2,897/3,116 Sec#203/265 |
| Net Assets | $248M | US#2,585/3,116 Sec#168/265 |
| Employees | 60 | US#2,679/3,116 Sec#201/265 |
| Value | ||
| P/B | 2.01x | US#1,268/3,116 Sec#57/265 |
| P/S | 820.55x | US#2,980/3,116 Sec#194/265 |
| FCF Yield | -15.28% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -46.30% | US#2,656/3,116 Sec#150/265 |
| ROA | -37.31% | US#2,928/3,116 Sec#182/265 |
| Op. Margin | -16740.95% | US#2,848/3,116 Sec#187/265 |
| Financial Health | ||
| Debt Ratio | 24.08% | US#267/3,116 Sec#89/265 |
| Total Debt | $3M | US#2,933/3,116 Sec#228/265 |
| FCF | $-76M | US#2,587/3,116 Sec#130/265 |
| Cash | $81M | US#2,338/3,116 Sec#189/265 |
| Current Ratio | 5.18x | US#452/3,116 Sec#136/265 |
| Performance | ||
| 1Y Return | -58.89% | US#2,989/3,116 Sec#248/265 |
| 1M Return | -11.56% | US#2,560/3,116 Sec#191/265 |
| From 52W High | -76.04% | US#3,027/3,116 Sec#247/265 |
| 1Y MDD | -78.04% | US#3,022/3,116 Sec#242/265 |
| Trading | ||
| Volume | 299,884 shares | US#2,493/3,116 Sec#236/265 |
| Trading Value | $3M | US#2,871/3,116 Sec#238/265 |
| Per Share | ||
| EPS | $-1.90 | US—/3,116 Sec—/265 |
| BPS | $4.10 | US#2,341/3,116 Sec#136/265 |
Company Info
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.